Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 3/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113361 | 0.80 | ALDH1A1 (0.49) | CACNA1GCACNA1HCACNA1IMEN1KMT2A | |
| SCHEMBL633494 | 0.79 | TSHR (0.32) | MEN1KMT2ARAB9AALDH1A1GAA | |
| SCHEMBL2114944 | 0.79 | MEN1 (0.37) | CACNA1GCACNA1HCACNA1IMEN1KMT2A | |
| SCHEMBL15162641 | 0.78 | CACNA1G (0.38) | CACNA1GCACNA1HCACNA1IMEN1KMT2A | |
| SCHEMBL12468720 | 0.75 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1GAA | |
| SCHEMBL634112 | 0.75 | GABRA1 (0.33) | — | |
| SCHEMBL3440072 | 0.75 | PTPN1 (0.42) | CACNA1GCACNA1HCACNA1IMEN1KMT2A | |
| SCHEMBL2113557 | 0.69 | TSHR (0.39) | MEN1KMT2AALDH1A1GAA | |
| SCHEMBL2115672 | 0.69 | CACNA1G (0.47) | CACNA1GCACNA1HCACNA1IRAB9ANPC1 | |
| SCHEMBL634378 | 0.68 | TSHR (0.38) | MEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | H1-3, CHRM2, TBL3 | CACNA1G 4468/4885CACNA1H 4418/4885CACNA1I 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.